Verve Therapeutics' stock soared 40% due to positive trial results for familial hypercholesterolemia treatment.

From Nasdaq MarketSite: 2025-04-18 18:36:00

Verve Therapeutics (NASDAQ: VERV) saw a 40% jump in stock price this week after positive results from a phase 1b clinical trial of VERVE-102 targeting familial hypercholesterolemia. Analysts responded with bullish notes and raised price targets. The treatment showed efficacy in reducing LDL-C levels and was well-tolerated with no serious adverse events reported. While some analysts, like Eric Joseph of JPMorgan Chase, lowered their price targets, overall sentiment remained positive. BMO Capital’s Kostas Biliouris reiterated an outperform recommendation, noting the drug’s performance exceeded expectations and had a favorable safety profile.

For investors looking to allocate $1,000, Stock Advisor has revealed the 10 best stocks to buy right now, boasting a total average return of 792% compared to the S&P 500’s 153%. Joining Stock Advisor gives access to these stock picks. JPMorgan Chase, an advertising partner of Motley Fool Money, has no position in the stocks mentioned. The author, Eric Volkman, does not hold positions in any mentioned stocks. The Motley Fool holds positions in and recommends JPMorgan Chase.



Read more at Nasdaq MarketSite: Why Verve Therapeutics Zoomed 40% Higher This Week